EyePoint Pharmaceuticals, Inc. (EYPT)
NASDAQ: EYPT · Real-Time Price · USD
9.64
-0.73 (-7.04%)
At close: Jun 27, 2025, 4:00 PM
9.70
+0.06 (0.62%)
After-hours: Jun 27, 2025, 4:46 PM EDT
EyePoint Pharmaceuticals Revenue
EyePoint Pharmaceuticals had revenue of $24.45M in the quarter ending March 31, 2025, with 109.29% growth. This brings the company's revenue in the last twelve months to $56.04M, up 12.04% year-over-year. In the year 2024, EyePoint Pharmaceuticals had annual revenue of $43.27M, down -5.97%.
Revenue (ttm)
$56.04M
Revenue Growth
+12.04%
P/S Ratio
9.63
Revenue / Employee
$339,648
Employees
165
Market Cap
663.35M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 43.27M | -2.75M | -5.97% |
Dec 31, 2023 | 46.02M | 4.61M | 11.14% |
Dec 31, 2022 | 41.40M | 4.47M | 12.09% |
Dec 31, 2021 | 36.94M | 2.50M | 7.27% |
Dec 31, 2020 | 34.44M | 14.07M | 69.10% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
EYPT News
- 12 days ago - EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 16 days ago - EyePoint Stock: Retaining My 'Risky Buy' Call - Pivotal Data Due Early 2026 - Seeking Alpha
- 4 weeks ago - EyePoint Announces Participation at Upcoming Investor Conferences - GlobeNewsWire
- 4 weeks ago - EyePoint Completes Enrollment in Pivotal Phase 3 LUGANO Trial of DURAVYU™ for Treatment of Wet Age-Related Macular Degeneration - GlobeNewsWire
- 6 weeks ago - EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - EyePoint Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Developments - GlobeNewsWire
- 2 months ago - EyePoint to Report First Quarter 2025 Financial Results on May 7, 2025 - GlobeNewsWire